Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Sabrina L. Browning, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA, Madhav V. Dhodapkar, MBBS, Stuart Seropian, MD, Alfred Ian Lee, MD PhD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD PhD, Andrew Haims, MD, Natalia Neparidze, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136478

Published: 2020

Journal Articles

Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141603

Published: 2020

Journal Articles

High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142854

Published: 2020

Journal Articles

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Blood (2019) 134 (Supplement_1): 450.

https://doi.org/10.1182/blood-2019-130442

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition

Melissa A. Fischer, MSc, PhD, Maria Arrate, MSc, Merrida A Childress, PhD, Brianna N Smith, MD MS, Yuanbin Song, MD, Rana Gbyli, MS, Thomas Stricker, MD PhD, Stephanie Halene, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2982.

https://doi.org/10.1182/blood-2019-126578

Published: 2019

Journal Articles

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

Xiaofei He, B.S., Caleb Hawkins, B.S., Lauren Lawley, B.S., Mark Wunderlich, MS, Benjamin Mizukawa, Xiang-ming Zha, PhD, Stephanie Halene, MD, Jing Fang, MD PhD

Blood (2019) 134 (Supplement_1): 2661.

https://doi.org/10.1182/blood-2019-125455

Published: 2019

Journal Articles

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, PhD, Jeff Grotzke, PhD, Sophia Gayle, PhD, Marylens Hernandez, PhD, Stephanie Halene, MD, Peter R Young, PhD, Langdon L Miller, MD, Tian Xu, PhD, Jonathan Rothberg, PhD, Henri Lichenstein, PhD

Blood (2019) 134 (Supplement_1): 2664.

https://doi.org/10.1182/blood-2019-125770

Published: 2019

Journal Articles

U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex

Blood (2019) 134 (Supplement_1): 1230.

https://doi.org/10.1182/blood-2019-130759

Published: 2019

Journal Articles

In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice

Yuanbin Song, MD, Liang Shan, PhD, Rana Gbyli, MS, Wei Liu, PhD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Ashley Qin, Amisha Patel, MS, Yimeng Gao, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, David Urbonas, Jonathan Alderman, PhD, Stephanie Halene, MD, Richard Flavell, PhD

Blood (2019) 134 (Supplement_1): 338.

https://doi.org/10.1182/blood-2019-130701

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Lohith Gowda, MD MRCP, Karl Hager, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5173.

https://doi.org/10.1182/blood-2019-127162

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism

Blood (2018) 132 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2018-99-115529

Published: 2018

Journal Articles

Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice

Juliana Xavier-Ferrucio, PhD, Xiuqi Li, Vanessa Scanlon, PhD, Ping-Xia Zhang, PhD, Nadia Ayala-Lopez, PhD MT(ASCP), Toma Tebaldi, PhD, Stephanie Halene, MD, Karin E. Finberg, MD PhD, Diane S. Krause, MD PhD

Blood (2018) 132 (Supplement 1): 2.

https://doi.org/10.1182/blood-2018-99-115124

Published: 2018

Journal Articles

Proton Sensor GPR68 Is Essential to Maintain Myeloid Malignancies

Xiaofei He, B.S., Mark Wunderlich, MS, Benjamin Mizukawa, MD, James C. Mulloy, PhD, Saran Feng, MD, PhD, Lauren Lawley, B.S., Caleb Hawkins, B.S., Wenxin Fan, B.S., Guokun Zhou, PhD, Xiang-ming Zha, PhD, Jiajia Zhang, PhD, Johnie Hodge, MD,PhD, Daping Fan, PhD, Stephanie Halene, MD, Jing Fang, MD PhD

Blood (2018) 132 (Supplement 1): 1353.

https://doi.org/10.1182/blood-2018-99-110399

Published: 2018

Journal Articles

Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis

Yimeng Gao, PhD, Radovan Vasic, MD, Toma Tebaldi, PhD, Yuanbin Song, MD, Rhea Teng, Poorval Joshi, PhD, Gabriella Viero, PhD, Andrew Xiao, PhD, Pedro Batista, PhD, Huabing Li, PhD, Richard Flavell, PhD, Stephanie Halene, MD

Blood (2018) 132 (Supplement 1): 3825.

https://doi.org/10.1182/blood-2018-99-119699

Published: 2018

Journal Articles

PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia

Tae Kon Kim, MD PhD, Xue Han, PhD, Jun Wang, PhD, Miguel Sanmamed, MD, Tianxiang Zhang, PhD, Stephanie Halene, MD PhD, Manoj M Pillai, MD, Jun Lu, PhD, Mina Xu, MD, Amer M. Zeidan, MD, Steven D. Gore, MD, Madhav V Dhodapkar, MBBS, Lieping Chen, MD PhD

Blood (2017) 130 (Supplement 1): 2658.

https://doi.org/10.1182/blood.V130.Suppl_1.2658.2658

Published: 2017

NARROW

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice

High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex

In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism

Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice

Proton Sensor GPR68 Is Essential to Maintain Myeloid Malignancies

Mettl3 Mediated m6A Modification Is Essential in Fetal Hematopoiesis

PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only